HR 8339
Drug Origin Transparency Act of 2026
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 3:14 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill, the Drug Origin Transparency Act of 2026, aims to increase transparency in the pharmaceutical supply chain. It requires manufacturers to provide more detailed information about the sources of active pharmaceutical ingredients and other materials used in drug production, including supplier identities and quantities. The bill also mandates that drug labels include the original manufacturer’s name, place of business, and unique facility identifier, promoting accountability and traceability within the drug supply chain.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.